MannKind Corp. confirmed that it received $16.7 million on Feb. 17, upon closing the sale of the Mann Biomedical Park property at the Rye Canyon Loop in Valencia, net of closing costs.   About MannKind Corp. MannKind Corp. focuses on the discovery, development and commercialization of therapeutic...

Valencia-based MannKind Corp. confirmed Tuesday that it received $30.6 million from Sanofi on Jan. 6, 2017, representing the balance of the accelerated insulin “put” option previously exercised by MannKind. This payment was made pursuant to a previously disclosed agreement reached with Sanofi on...

MannKind Corporation announced Friday that Stuart A. Tross, Ph.D., has joined the company as its Chief People Officer, with responsibilities for Human Resources, Information Technology and West Coast Facilities. MannKind Corporation also confirmed that following the completion of initial formulation...

Valencia-based biotech MannKind Corp. reported financial results Monday for the second quarter and the six months ended June 30, 2016. For the second quarter ended June 30, 2016, total operating expenses were $19.1 million as compared to $24.1 million for the same quarter in 2015. Research and development...

Valencia-based MannKind Corp. announced results of two late-breaking posters and four additional analyses of Afrezza® (insulin human) Inhalation Powder, including three posters demonstrating a faster onset of action and a shorter duration than rapid-acting insulin analogs in patients with diabetes mellitus....

Valencia-based MannKind Corp. reported financial results for the first quarter ended March 31, 2016. For the first quarter of 2016, total operating expenses were $20.0 million, or 6 cents per share, as compared to $21.7 million for the same quarter in 2015. (Wall Street expected a loss of 4 cents.) Research...

Joseph Saldanha Valencia-based MannKind Corp. has announced two senior appointments to its commercial organization. Joining the Company are Joseph Saldanha as Vice President of Marketing and Agustin (Tino) Quintero as Vice President of Market Value, Access and Trade. Both will report to Michael Castagna,...

Valencia-based MannKind Corp. has assumed responsibility for the worldwide development and commercialization of Afrezza (insulin human) Inhalation Powder from Sanofi, effective Tuesday, in a transition that ensures patients will not experience any interruption in their treatment. Under terms of the transfer...

Incoming: Michael E. Castagna Valencia biomed MannKind Corp. announced Monday that Michael E. Castagna, Pharm.D., has joined the company as its Chief Commercial Officer, effective immediately. Dr. Castagna will lead commercialization efforts for Afrezza, reporting to Matthew Pfeffer, Chief Executive...

[Valencia, Calif.] – MannKind Corp. reported with deep sadness Friday the passing of Alfred E. Mann, age 90, the company’s Chairman Emeritus. Mr. Mann was the Chairman of the Board of MannKind from 2001 until February 2016 and, from November 2003 until January 2015, was its Chief Executive Officer....